MA55893A - Procédés d'administration de certains inhibiteurs de vmat2 - Google Patents
Procédés d'administration de certains inhibiteurs de vmat2Info
- Publication number
- MA55893A MA55893A MA055893A MA55893A MA55893A MA 55893 A MA55893 A MA 55893A MA 055893 A MA055893 A MA 055893A MA 55893 A MA55893 A MA 55893A MA 55893 A MA55893 A MA 55893A
- Authority
- MA
- Morocco
- Prior art keywords
- administration
- methods
- vmat2 inhibitors
- certain
- certain vmat2
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845599P | 2019-05-09 | 2019-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55893A true MA55893A (fr) | 2022-03-16 |
Family
ID=70919120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055893A MA55893A (fr) | 2019-05-09 | 2020-05-08 | Procédés d'administration de certains inhibiteurs de vmat2 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200397779A1 (fr) |
| EP (1) | EP3965764A1 (fr) |
| JP (1) | JP2022531696A (fr) |
| KR (1) | KR20220007105A (fr) |
| CN (1) | CN114340624A (fr) |
| AU (1) | AU2020270145A1 (fr) |
| BR (1) | BR112021020709A2 (fr) |
| CA (1) | CA3136466A1 (fr) |
| EA (1) | EA202193012A1 (fr) |
| IL (1) | IL287902A (fr) |
| JO (1) | JOP20210274A1 (fr) |
| MA (1) | MA55893A (fr) |
| MX (1) | MX2021013132A (fr) |
| SG (1) | SG11202111465RA (fr) |
| TW (1) | TW202108138A (fr) |
| WO (1) | WO2020227672A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7199361B2 (ja) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| CN111836543A (zh) | 2017-10-10 | 2020-10-27 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
| US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| KR20210044817A (ko) | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| KR20240027780A (ko) * | 2021-06-30 | 2024-03-04 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 조현병의 부가적 치료에 사용하기 위한 발베나진 |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
| WO2023172849A1 (fr) * | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbénazine, inhibiteur de vmat2, en tant que base libre d'un tosylate ou d'un sel de ditosylate, destinée à être utilisée dans le traitement de la chorée associée à la maladie de huntington |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US952A (en) | 1838-09-27 | I antoni bengini | ||
| US10065A (en) | 1853-10-04 | Improvement in machines for topping cotton jn the field | ||
| RS62782B1 (sr) * | 2014-05-06 | 2022-01-31 | Neurocrine Biosciences Inc | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
| WO2016210180A2 (fr) * | 2015-06-23 | 2016-12-29 | Neurocrine Biosciences, Inc. | Inhibiteurs de vmat2 pour le traitement de maladies ou troubles neurologiques |
| JP7199361B2 (ja) * | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| WO2018164996A1 (fr) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Posologie pour la valbénazine |
| KR20210044817A (ko) * | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
-
2020
- 2020-05-08 SG SG11202111465RA patent/SG11202111465RA/en unknown
- 2020-05-08 TW TW109115397A patent/TW202108138A/zh unknown
- 2020-05-08 EA EA202193012A patent/EA202193012A1/ru unknown
- 2020-05-08 JO JOP/2021/0274A patent/JOP20210274A1/ar unknown
- 2020-05-08 CA CA3136466A patent/CA3136466A1/fr active Pending
- 2020-05-08 MA MA055893A patent/MA55893A/fr unknown
- 2020-05-08 MX MX2021013132A patent/MX2021013132A/es unknown
- 2020-05-08 EP EP20729429.9A patent/EP3965764A1/fr active Pending
- 2020-05-08 BR BR112021020709A patent/BR112021020709A2/pt unknown
- 2020-05-08 CN CN202080034710.XA patent/CN114340624A/zh active Pending
- 2020-05-08 AU AU2020270145A patent/AU2020270145A1/en active Pending
- 2020-05-08 JP JP2021565932A patent/JP2022531696A/ja active Pending
- 2020-05-08 WO PCT/US2020/032188 patent/WO2020227672A1/fr unknown
- 2020-05-08 KR KR1020217039903A patent/KR20220007105A/ko active Search and Examination
- 2020-08-31 US US17/007,710 patent/US20200397779A1/en not_active Abandoned
-
2021
- 2021-10-21 US US17/506,883 patent/US20220040169A1/en not_active Abandoned
- 2021-11-08 IL IL287902A patent/IL287902A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021013132A (es) | 2021-11-25 |
| BR112021020709A2 (pt) | 2021-12-14 |
| US20200397779A1 (en) | 2020-12-24 |
| JP2022531696A (ja) | 2022-07-08 |
| EP3965764A1 (fr) | 2022-03-16 |
| SG11202111465RA (en) | 2021-11-29 |
| IL287902A (en) | 2022-01-01 |
| TW202108138A (zh) | 2021-03-01 |
| WO2020227672A1 (fr) | 2020-11-12 |
| AU2020270145A1 (en) | 2021-12-23 |
| CA3136466A1 (fr) | 2020-11-12 |
| KR20220007105A (ko) | 2022-01-18 |
| US20220040169A1 (en) | 2022-02-10 |
| JOP20210274A1 (ar) | 2023-01-30 |
| CN114340624A (zh) | 2022-04-12 |
| EA202193012A1 (ru) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53239A (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| MA55893A (fr) | Procédés d'administration de certains inhibiteurs de vmat2 | |
| MA53388A (fr) | Inhibiteurs d'inflammasome nlrp3 | |
| DK3966207T3 (da) | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3966206T3 (da) | Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf | |
| MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| JP2018172409A5 (ja) | １５−ｈｅｐｅを含む組成物および同組成物を使用する方法 | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP4003344A4 (fr) | Inhibiteurs deutérés de la voie de signalisation mk2 et méthodes d'utilisation de ceux-ci | |
| MA54261A (fr) | Inhibiteurs de pcsk9 et leurs procédés d'utilisation | |
| DK3524609T3 (da) | Fremgangsmåde til fremstilling af 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromenderivater, optiske isomerer deraf og mellemprodukter fra processen | |
| DK3797107T3 (da) | Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| EA201991595A1 (ru) | Активатор nrf2 | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| IL289127A (en) | ppm1a inhibitors and methods of using them | |
| IL283295A (en) | gli1 inhibitors as therapeutic agents | |
| MA53672A (fr) | Inhibiteurs de cdpk1, compositions et procédés associés | |
| IL307678A (en) | Methods of administering certain VMAT2 inhibitors | |
| MA54699A (fr) | Procédés d'introduction d'allergènes alimentaires | |
| MA56507A (fr) | Nouveaux inhibiteurs d'egfr | |
| MA55203A (fr) | Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase | |
| MA51151A (fr) | Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase |